Skip to main content

Managing Your IP Litigation Spend: Containing Costs and Maintaining Quality


Speaker(s): Jonathan A. Harris, Lauren Rabinovic
Recorded on: Dec. 9, 2015
PLI Program #: 167227

A patent trial lawyer with nearly two decades of experience, Jonathan Harris focuses his practice on patent litigation and contested Patent Office proceedings in the biomedical field. Clients describe Jonathan as "an excellent patent analyst" and "skilled at translating complex technical subjects into English." Jonathan has worked with industry leaders such as Actavis (now Teva), Johnson & Johnson, Par (now Endo), Thermo Fisher and Unilever. He has successfully litigated and tried cases involving products worth billions of dollars.

With experience in both patent litigation and prosecution, Jonathan seeks to separate the strongest from the weakest positions early in each case.  His approach narrows cases to what really matters at trial and helps identify unique and defensible positions others might not have considered.

Given his focus on clients’ business objectives and having earned an MBA, Jonathan also tries to see the bigger picture of every matter — not only from a legal, but also a commercial perspective.  Jonathan prides himself on counseling clients to reduce litigation risk and craft business resolutions through effective pre-trial strategies.  He also regularly provides advice on pre-litigation matters, prepares patent licenses and conducts IP due diligence.

Outside the firm, Jonathan co-founded the Janet Bond Arterton IP Inn of Court. He has also tried cases for the Commission on Human Rights and Opportunities on a pro bono basis.


I have been providing client advice as both a USPTO-registered Patent Agent and Attorney for over 15 years.  My private practice focused on drafting PTC and US patent applications, prosecuted US patent applications, and provided opinion and due diligence support to the attorneys at the firm for academic, US, and multinational corporations in relation to pharmaceutical, biologics, diagnostics, and gene therapies.  My in-house roles have focused on providing clearance, due diligence, and litigation activities related to branded and generic pharmaceutical products that are manufactured at sites throughout the globe and are marketed in the Americas.